Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.…
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 THERAPEUTICS (NASDAQ: CAMP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 48 employees.
The shares were at 3.790 USD on 20 November 2026, up 2.2% over 52 weeks. Its 52-week range is 2.900 USD to 7.750 USD: the price is 51.1% below the high and 30.7% above the low.
Its market capitalisation is 237.84M USD.
CAMP4 THERAPEUTICS reports return on equity of -168.5% and revenue up 138.9% year over year.
It holds more cash than debt, a net cash position of 118.07M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 10.22 USD is 169.7% above the current price.